Target intelligence / Profile preview

Vδ2-T cell receptor (Vδ2 TCR)

Target
Vδ2 TCR
Molecular classification
Receptor, T cell receptor (immune receptor), γδ T cell receptor
01

Overview

The Vδ2-T cell receptor is a T cell receptor variant defined by its use of the Vδ2 gene segment. It is predominantly found in peripheral blood γδ T cells of adults, almost always paired with the Vγ9 chain, forming the Vγ9Vδ2 TCR heterodimer. This receptor recognizes small, non-peptidic phosphorylated antigens (phosphoantigens) that accumulate in infected or malignant cells, but does so indirectly: phosphoantigens bind to intracellular domains of the butyrophilin family protein BTN3A1, which then undergoes a conformational change to present an activation signal to the Vδ2 TCR. Vγ9Vδ2 T cells mediate rapid, potent cytotoxic immune responses, play a role in anti-tumor and anti-microbial immunity, and serve as promising effectors for immunotherapy. Vδ2 T cells also display APC-like properties under certain activation conditions. Their activation, homing, phenotype, and function are modulated by chemokine receptors and co-stimulatory molecules, and their precise mechanism of phosphoantigen antigen recognition remains an active area of research.

Other names
Vδ2 TCRVγ9Vδ2 TCR (Vγ9-Vδ2 T cell receptor)Vδ2+ T cell receptorGamma delta T cell receptor Vδ2
02

Mechanism of action

Induction of cytotoxic T cell response via recognition of phosphoantigen-presenting BTN3A1 on tumor/infected cells (butyrophilin-dependent activation) Antigen-independent cytotoxicity mediated by NK cell receptors, such as NKG2D, expressed on Vδ2 T cells

03

Biological functions

Immune responseAntigen recognitionAntitumor immunityAnti-microbial immunityCytotoxicityProfessional antigen presentation (APC function)
04

Disease associations

CancerInfection (including bacterial, viral)Inflammation
05

Safety considerations

Overstimulation risks including cytokine release syndrome (CRS) during adoptive transferPotential for off-target cytotoxicity (collateral tissue damage)Immune exhaustion following repeated stimulationLimited expansion capacity in subsets (affecting efficacy and persistence)
06

Interacting drugs

Zoledronate (and other nitrogen-containing bisphosphonates, these induce isopentenyl pyrophosphate/IPP accumulation that activates Vδ2 T cells)

3 more in the full profile.

07

Biomarkers

Frequency of Vγ9Vδ2 T cells in peripheral blood (for immunotherapy monitoring)BTN3A1 expression and phosphoantigen accumulation in target tissuesChemokine receptor expression (e.g., CCR5, CCR6, CD161) that identifies Vδ2 T cell subsets

Beyond the preview

Go deeper on Vδ2-T cell receptor (Vδ2 TCR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vδ2-T cell receptor (Vδ2 TCR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call